PBL gains approval to advance next generation anthrax vaccine to Phase 1 clinical trial

Porton Biopharma Ltd (PBL) has today announced that it has signed a modification to its contract (HHSN272201600045C) with the US National Institute of Health’s National Institute of Allergy and Infectious Diseases (NIAID) to advance a next generation intra-nasal anthrax vaccine into the clinical-trial phase. The contract modification is worth US $4.5 million and follows approval by the US Food and Drug Administration (FDA) of the investigational new drug (IND) application

read more

PBL case study featured in July edition of Manufacturing Chemist

Purification expertise

In this case study, Dr David Gervais, Head of Product and Fermentation Development at Porton Biopharma  describes how a non-GMP enzyme manufacturing process has been successfully converted from a native to a recombinant one using bioinformatics and next-generation sequencing (NGS).

Demonstrating PBL’s capability to deliver significant improvements in yield, purity and activity for customer’s products.

read more

Automating the production of life-saving drugs

PBL is featured in a technical article in Manufacturing Chemist on “Automating the production of life-saving drugs” in regards to the new Bosch integrated filling line that we have installed to meet the growing demand for our Erwinase product, which is used to treat childhood leukaemia.

read more